Journal of International Oncology››2022,Vol. 49››Issue (12): 724-728.doi:10.3760/cma.j.cn371439-20220609-00142
• Original Articles •Previous ArticlesNext Articles
Liu Cantong1,2, Huang Xinyi3, Chen Liuyi1, Chen Hao4, Peng Yuhui1,2, Huang Xuchun1()
Received:
2022-06-09Revised:
2022-06-27Online:
2022-12-08Published:
2023-01-05Contact:
Huang Xuchun E-mail:313623874@qq.comSupported by:
Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer[J]. Journal of International Oncology, 2022, 49(12): 724-728.
[1] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi:10.3322/caac.21660 |
[2] | Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancer early diagnosis[J]. World J Gastroenterol, 2019, 25(17): 2029-2044. DOI: 10.3748/wjg.v25.i17.2029. doi:10.3748/wjg.v25.i17.2029 |
[3] | Jin L, Shen F, Weinfeld M, et al. Insulin growth factor binding protein 7 (IGFBP7)-related cancer and IGFBP3 and IGFBP7 crosstalk[J]. Front Oncol, 2020, 10: 727. DOI: 10.3389/fonc.2020.00727. doi:10.3389/fonc.2020.00727pmid:32500027 |
[4] | Srisawat N, Kellum JA. The role of biomarkers in acute kidney injury[J]. Crit Care Clin, 2020, 36(1): 125-140. DOI: 10.1016/j.ccc.2019.08.010. doi:S0749-0704(19)30073-9pmid:31733675 |
[5] | Akiel M, Guo C, Li X, et al. IGFBP7 deletion promotes hepatoce-llular carcinoma[J]. Cancer Res, 2017, 77(15): 4014-4025. DOI: 10.1158/0008-5472.CAN-16-2885. doi:10.1158/0008-5472.CAN-16-2885 |
[6] | Chen C, Tian X, Zhao X, et al. Clinical study of serum IGFBP7 in predicting lymphatic metastasis in patients with lung adenocarcinoma[J]. Curr Probl Cancer, 2020, 44(6): 100584. DOI: 10.1016/j.currproblcancer.2020.100584. doi:10.1016/j.currproblcancer.2020.100584 |
[7] | Zhao Q, Zhao R, Song C, et al. Increased IGFBP7 expression corre-lates with poor prognosis and immune infiltration in gastric cancer[J]. J Cancer, 2021, 12(5): 1343-1355. DOI: 10.7150/jca.50370. doi:10.7150/jca.50370 |
[8] | Xu YW, Chen H, Guo HP, et al. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma[J]. Gastric Cancer, 2019, 22(3): 546-557. DOI: 10.1007/s10120-018-0894-y. doi:10.1007/s10120-018-0894-y |
[9] | 赵丹瑜, 李霞, 钟捷, 等. 胰岛素样生长因子结合蛋白7基因在胃癌细胞中的表达及甲基化调控[J]. 上海交通大学学报(医学版), 2009, 29(9): 1062-1065. |
[10] | 贺德志. 胰岛素样生长因子结合蛋白7在人类胃癌中的表达及其生物学功能研究[D]. 郑州: 郑州大学, 2014. |
[11] | Li D, She J, Hu X, et al. The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA-RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis[J]. Oncogene, 2021, 40(35): 5403-5415. DOI: 10.1038/s41388-021-01948-6. doi:10.1038/s41388-021-01948-6pmid:34274947 |
[12] | Dang W, Cao P, Yan Q, et al. IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis[J]. Cancer Lett, 2021, 523: 135-147. DOI: 10.1016/j.canlet.2021.10.006. doi:10.1016/j.canlet.2021.10.006pmid:34634383 |
[13] | Qiu MZ, He CY, Lu SX, et al. Prospective observation: clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients[J]. Int J Cancer, 2020, 146(1): 272-280. DOI: 10.1002/ijc.32490. doi:10.1002/ijc.32490 |
[14] | Huang X, Hong C, Peng Y, et al. The diagnostic value of serum IGFBP7 in patients with esophageal squamous cell carcinoma[J]. J Cancer, 2019, 10(12): 2687-2693. DOI: 10.7150/jca.32393. doi:10.7150/jca.32393pmid:31258777 |
[15] | Liu CT, Xu YW, Guo H, et al. Serum insulin-like growth factor binding protein 7 as a potential biomarker in the diagnosis and prognosis of esophagogastric junction adenocarcinoma[J]. Gut Liver, 2020, 14(6): 727-734. DOI: 10.5009/gnl19135. doi:10.5009/gnl19135 |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Hu Tingting, Wang Yuehua.Electronic nose and nematode nose as new tool for early cancer screening[J]. Journal of International Oncology, 2024, 51(4): 223-226. |
[4] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[5] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[6] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[7] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[8] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[9] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[10] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[11] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[12] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[13] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[14] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[15] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||